Previous 10 | Next 10 |
BETHESDA, Md. , Aug. 11, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for a...
BETHESDA, Md. , July 24, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Com...
The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...
Northwest Biotherapeutics ( OTCQB:NWBO ): Q1 GAAP EPS of $0.00. Revenue of $0.57M (+67.6% Y/Y) Press Release More news on: Northwest Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
BETHESDA, Md. , June 2, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Gl...
In April, Northwest Biotherapeutics (OTC: NWBO) disclosed that its phase 3 clinical trial to evaluate its cancer immunotherapy vaccine DCVax-L in treating glioblastoma, the most invasive form of brain cancer, may finally be coming to an end. The company believes it will reach the r...
BETHESDA, Md. , April 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers , will discuss the projected schedule f...
BETHESDA, Md. , Feb. 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder's Meeting will be held on April 18, 2020 ...
Company Thesis Northwest Biotherapeutics' ( NWBO ) flagship product, DCVax (Dendritic cell vaccine for the treatment of glioblastoma) has seen its clinical investigation running well beyond schedule. While preliminary results on the entire study population are out, they raise more questions ...
As a statistician and math enthusiast, it was torture reviewing released Northwest Bio’s ( OTCQB:NWBO ) blinded data, and updated statistics showcasing the blinded results of the DCVax-L Phase III trial from back in June 2018. Reading the positive outlook of the trial through the ey...
News, Short Squeeze, Breakout and More Instantly...
Northwest Biotherapeutics Inc. Company Name:
NWBO Stock Symbol:
OTCMKTS Market:
Northwest Biotherapeutics Inc. Website:
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities PR Newswire Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- No...
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...